| Autor: |
Velasquez M; Gilead Sciences, Inc., Foster City, CA 94404, USA., O'Sullivan C; Gilead Sciences, Inc., Foster City, CA 94404, USA., Brockett R; Gilead Sciences, Inc., Foster City, CA 94404, USA., Mikels-Vigdal A; Gilead Sciences, Inc., Foster City, CA 94404, USA., Mikaelian I; Gilead Sciences, Inc., Foster City, CA 94404, USA., Smith V; Gilead Sciences, Inc., Foster City, CA 94404, USA., Greenstein AE; Gilead Sciences, Inc., Foster City, CA 94404, USA.; Corcept Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA. |
| Abstrakt: |
Matrix metalloproteinase 9 (MMP9), a protease implicated in multiple diseases, is secreted as an inactive zymogen and requires proteolytic removal of the pro-domain for activation. The relative levels and functionality of the pro- and active-MMP9 isoforms in tissues are not characterized. We generated a specific antibody that distinguishes an active form of MMP9, F107-MMP9, from the inactive pro-MMP9 isoform. Using multiple in vitro assays and specimen types, we show that F107-MMP9 expression is localized and disease-specific compared with its more abundant parental pro-form. It is detected around sites of active tissue remodeling, including fistulae of inflammatory bowel and dermal fissures in hidradenitis suppurativa, and is expressed by myeloid cells, including macrophages and neutrophils. Together, our findings provide insights into the distribution and potential role of MMP9 in inflammatory diseases. |
